Tran CD, Ball JM, Sundar S, Coyle P, Howarth GS
The authors highlight three urgent priorities: Reframing GLP1 receptor agonists as essential medicines to reduce multimorbidity and premature mortality Addressing inequitable access and affordability, particularly in low and middleincome countries Strengthening healthsystem capacity, alongside prevention and behavioural support, to deliver safe and effective obesity care As the paper makes clear, prevention and treatment are codependent, stigma remains a major barrier, and lessons from HIV show what is possible when access, advocacy and systems change move together.
Oral supplements are effective for mild deficiency and maintenance
A qualifying BMI or related health condition is typically required GLP-1 medications like semaglutide are usually prescribed to adults with a BMI over 30, or over 27 if they have a weight-related condition, such as high blood pressure, prediabetes, sleep apnea, or PCOS
A new class of peptides, such as chelating and bioactive peptides, represents a rapidly advancing frontier in precision medicine, offering novel, targeted, and safer alternatives for the treatment of diseases rooted in elemental imbalance and complex molecular dysfunction
